 | |
| Company type | Private |
|---|---|
| Industry | |
| Founded | 2019 |
| Headquarters | Boston, Massachusetts |
Key people | Mark Rus (Chief Executive Officer) |
| Website | delixtherapeutics |
Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[2] It was co-founded in 2019 by David E. Olson and Nick Haft.[3]
- ^ LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-06-08.
- ^ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-05-18.
- ^ Kathan, Jesse (December 13, 2021). "Harnessing Psychedelics for Healing". Comstock's magazine. Retrieved 2022-06-08.